Exclusive Summary

• Passport to Global Markets: The US-FDA GMP certification and existing US ANDA approval serve as valid reference country data, significantly accelerating registration processes in LatAm, MENA, and SEA markets.
• Differentiated Complex Generic: Unlike the red-ocean Immediate Release (IR) market, the Sustained-Release (SR) formulation has high technical barriers and limited competition, offering partners better pricing power.
• Superior Clinical Value: The once-daily dosing regimen improves patient adherence compared to traditional twice-daily tablets and reduces peak-valley plasma fluctuations, offering better tolerability for chronic Epilepsy and Migraine management.